Hanmi Pharmaceutical Group's affiliate, Coree Group, chaired by Jong Yoon Im, is on the brink of commercializing a natural substitute for the current 'Human Milk Oligosaccharides (HMO)' at the Coree Italy AAT Microbiome Research Institute. The strategic plan involves establishing a direct sales network in the European market through Coree Italy.

As reported by the company, the research on this HMO alternative is part of a collaborative project initiated in 2018 between Coree Group and the Gemelli Hospital of the Catholic University of Rome's 'Bio Bank.' This joint effort is focused on advancing the 'Symbiotics Food and Drug System' research. Coree Group is spearheading the research and development, while production and global market sales are entrusted to DXVX. The company emphasizes the crucial role of HMO in the mechanism through which breast milk mitigates the risk of various diseases, substantiating their claim with numerous research findings.

Dr. Han Sung Joon, Chief Technology Officer of DXVX, commented, "Despite the strides made by multinational companies in developing artificial HMO products through genetic modification technology, various challenges such as high production costs, low yield, biological rejection stemming from artificial manufacturing processes, and safety concerns related to new by-products underscore the necessity for alternatives."

He further stated, "The development of this HMO alternative is anticipated not only to provide essential products for infants and mothers but also to align with the societal objective of improving infant health, offering a solution to these challenges."